CD4+GranzB+CTLs could drive the progression of MS and were correlated with worse clinical outcome and prognosis in MS patients, while inhibiting the production of CD4+GranzB+CTLs could slow down the progression of MS disease. The gene discussed is CD4; the disease is myeloid sarcoma.